Central Retinal Vein Occlusion
📧 Sign up to get email alerts when something new happens for Central Retinal Vein Occlusion.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Hoffmann-La Roche reports a real-world, observational study to gain clinical insights into Roche ophthalmology products across several retin…
-
CLINICAL_TRIALS trial_result · 2025-06-27Clinical Trial Update: 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) [Phase 2]
Phase 2 trial comparing the investigational agent 601 with ranibizumab in Central Retinal Vein Occlusion has completed.
-
CLINICAL_TRIALS trial_result · 2025-04-30Clinical Trial Update: Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections [NA]
A completed clinical trial examining whether spontaneous retinal artery pulses (SPARs) can prognosticate outcomes in central retinal vein oc…
-
CLINICAL_TRIALS trial_result · 2024-12-02Clinical Trial Update: Treatment of Central Retinal Vein Occlusion Using Stem Cells Study [Phase 1, Phase 2]
An update on a Phase 1/2 clinical trial evaluating stem cell therapy for central retinal vein occlusion, with results posted after study com…
-
CLINICAL_TRIALS trial_result · 2024-05-30Clinical Trial Update: Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO [Phase 4]
A Phase 4 trial evaluating bevacizumab and triamcinolone for macular edema due to central retinal vein occlusion was terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-05-16Clinical Trial Update: Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion [Phase 4]
Phase 4 study evaluating intravitreal aflibercept for macular edema due to central retinal vein occlusion has completed.
-
CLINICAL_TRIALS trial_result · 2024-01-18Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion [Phase 3]
Phase 3 results evaluate Faricimab for macular edema secondary to central retinal vein occlusion and hemiretinal vein occlusion. The trial s…
-
CLINICAL_TRIALS trial_result · 2022-08-08Clinical Trial Update: Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion [Phase 3]
Phase 3 trial comparing brolucizumab to aflibercept in macular edema due to central retinal vein occlusion was terminated with posted result…
-
CLINICAL_TRIALS trial_result · 2022-07-13Clinical Trial Update: Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion [Phase 3]
Phase 3 trial update for Conbercept ophthalmic injection in macular edema due to central retinal vein occlusion has completed.
-
FDA approval · 2022-06-09FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
The FDA approved a supplemental application for BYOOVIZ (ranibizumab-nuna) from Biogen, authorizing its use as a biosimilar to ranibizumab.
-
CLINICAL_TRIALS trial_result · 2021-03-17Clinical Trial Update: Minocycline to Treat Central Retinal Vein Occlusion [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating minocycline for central retinal vein occlusion (retinal vein occlusion).
-
CLINICAL_TRIALS trial_result · 2020-12-04Clinical Trial Update: Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen [Phase 4]
Phase 4 trial comparing injection frequency between aflibercept and ranibizumab in central retinal vein occlusion using a treat-and-extend r…
-
CLINICAL_TRIALS trial_result · 2020-07-08Clinical Trial Update: Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO [Phase 4]
Phase 4 clinical trial evaluating a treat-and-extend regimen of intravitreal aflibercept for macular edema due to central retinal vein occlu…
-
CLINICAL_TRIALS trial_result · 2019-11-13Clinical Trial Update: Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions [Phase 2, Phase 3]
Retrospective study on the effectiveness and safety of niacin and steroid eye drops for retinal vein occlusions; the trial was terminated wi…
-
FDA approval · 2019-08-12FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)
The FDA approved Regeneron's supplemental application for EYLEA (aflibercept), updating its labeling to reflect an expanded or modified indi…
-
CLINICAL_TRIALS trial_result · 2018-08-21Clinical Trial Update: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) [Phase 3]
Phase 3 clinical trial update for treatments in central retinal vein occlusion (SCORE2) has completed with results posted.
-
FDA approval · 2018-08-16FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)
FDA has approved a supplemental application for EYLEA (aflibercept) from Regeneron Pharmaceuticals, Inc. The approval indicates the suppleme…
-
CLINICAL_TRIALS trial_result · 2018-04-03Clinical Trial Update: Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO) [NA]
Completed head-to-head clinical trial comparing initial dexamethasone intravitreal implant (Ozurdex) versus bevacizumab (Avastin) for macula…
-
CLINICAL_TRIALS trial_result · 2017-10-18Clinical Trial Update: Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion [Phase 2, Phase 3]
A Phase 2/3 study evaluated Ozurdex 0.7 mg for improving bevacizumab efficacy in non-ischemic central retinal vein occlusion. The trial has …
-
CLINICAL_TRIALS trial_result · 2017-08-14Clinical Trial Update: Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) [Phase 1]
Phase 1 RAVE2 trial evaluating 2.0 mg ranibizumab for ischemic central retinal vein occlusion was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2017-04-24Clinical Trial Update: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) [Phase 3]
Phase 3 trial comparing intravitreal ranibizumab injections to sham control in Central Retinal Vein Occlusion; the study has completed and r…
-
CLINICAL_TRIALS trial_result · 2017-04-11Clinical Trial Update: Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion [Phase 4]
Phase 4 trial update evaluating widefield angiography-guided targeted-retinal photocoagulation with anti-VEGF injections for ischemic centra…
-
CLINICAL_TRIALS research · 2017-03-21Clinical Trial Update: Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
This clinical trial update reports on evaluating how well physicians understand safety and safe-use information for aflibercept (Eylea) in C…
-
CLINICAL_TRIALS trial_result · 2017-03-10Clinical Trial Update: Ranibizumab Treatment for Retinal Vein Occlusion [NA]
This document concerns ranibizumab for macular edema due to branch retinal vein occlusion or central retinal vein occlusion. The trial statu…
-
CLINICAL_TRIALS research · 2017-03-01Clinical Trial Update: Observation of Treatment Patterns With Lucentis in Approved Indications
An observational study examining how Lucentis is used in approved indications such as neovascular age-related macular degeneration and diabe…